MYCOLab Ai Logo - gold and army green

Prognostic model for gastric cancer patients with COVID-19 and network pharmacology study on treatment by lentinan

Summary

This study investigated how lentinan, a compound from shiitake mushrooms, might help treat patients who have both gastric cancer and COVID-19. Researchers identified five genes that predict patient outcomes and found that lentinan may work by controlling immune cell activity and reducing inflammation. The study suggests lentinan could be a useful additional treatment for this challenging combination of diseases, though more research is needed.

Background

Gastric cancer patients are more susceptible to COVID-19 with significantly worsened prognosis. Currently, there are no effective treatment options for patients with both conditions. Lentinan, a bioactive component from Lentinus edodes, possesses antiviral and antitumor properties.

Objective

To construct a prognostic model for gastric cancer/COVID-19 patients and use network pharmacology to reveal biological functions, drug targets, and molecular mechanisms of lentinan against this combined condition.

Results

Five key prognostic genes were identified: F5, SERPINE1, F2, RNASE3, and KYNU. Lentinan’s therapeutic effects involve modulation of neutrophil-related processes and NOD-like receptor and IL-17 signaling pathways. CXCL8, VEGFA, RNASE3, and F2 were identified as core targets with strong lentinan binding affinity.

Conclusion

Key prognostic genes were identified in gastric cancer/COVID-19 patients through prognostic model construction. Lentinan demonstrates potential as a complementary therapy through regulation of neutrophils and NOD-like receptor signaling pathways. Further clinical experiments are needed to verify these findings.
  • Published in:Scientific Reports,
  • Study Type:Bioinformatics Study,
  • Source: PMID: 39428405, DOI: 10.1038/s41598-024-76783-2
Scroll to Top